



May 25, 2019

Shalby/SE/2019-20/17

The Listing Department	Corporate Service Department
National Stock Exchange of India Ltd	BSE Limited
Mumbai 400 051.	Mumbai 400 001.
Covin Codo : CHALDY	
Scrip Code : SHALBY	Scrip Code: 540797

Sub: Investor Presentation for the Fourth Quarter and year ended 31st March 2019, disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("the SEBI LODR")

Dear Sir / Madam,

We are submitting herewith Investor Presentation on financial & operational performance of the Company for the Fourth Quarter and year ended 31st March 2019, which is also being made available on our website.

We request to take the same on your records and disseminate the same to the members.

Thanking you,

Yours sincerely,

For Shalby Limited

Jayesh Patel

Company Secretary & Compliance Officer

Encl.: as above





Investor Presentation Q4 FY19 & FY19

Important Disclosure


No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects, and future developments in its industry and its competitive and regulatory environment. Actual results may differ materially from these forward-looking statements due to a number of factors, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions in India. This communication is for general information purpose only, without regard to specific objectives, financial situations and needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any shares in the Company and neither any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation can not be copied and/or disseminated in any manner.

...because passion drives perfection...

...and perfection drives

performance





Shalby Limited

A proxy for growth in the Indian Healthcare space



Current Scale of Operations

11 Hospitals

2,012* Total Bed Capacity

1,102** Operational beds

887 Census Beds

165 Non Census Beds

55% Operating bed to total bed capacity

47% Bed Occupancy (based on census beds)

31% 12 year CAGR Revenue

36% 12 year CAGR EBITDA

500+ Doctors & 2600+ Support Staff

- Ouble-digit return ratios against industry trend of single-digit
- Consistently superior ROCE of mature hospitals

^{**}The operational bed count of 1,102 considers 50 operational beds at Zynova-Shalby Hospital, Mumbai, for which no other operational parameters are tracked







Dr. Vikram ShahChairman & Managing
Director

Qualifications

Academic Qualifications:

- MBBS
- MS (Orthopaedics)

Professional Qualifications

- AO Basic Course (London)
- F.A.O.A.A (Switzerland)
- F.A.I.S.F (Germany)


Achievements

- Over two and a half decades of professional work experience across UK, USA and India. Serving as Director, Department of Knee Replacement at Shalby Hospitals since 1993
- Dr. Shah innovated zero '0' Technique in 2011 and was awarded the Double Helical Award 2017, for the innovation
 - Reduction of surgery time: 2.5 hours to 22 minutes
 - Reduction in patient stay: 15 days to 3 days
 - > Drastic fall in infection rates due to minimum incision
- Invented the OS Needle, which is thick bore reverse cutting needle used in attaching soft tissues to the bone. Before the invention of the Needle, surgeons had to use complicated soft tissue procedures that had a very high failure rate. The needle can be attached with commonly available vicryl thread
- President of Indian Society of Hip & Knee Surgeons (ISHKS) for the year 2010-11
- Part of joint international faculty for development of new joints by Zimmer Inc., USA
- Receiver of several awards and accolades by reputed organizations



Our Journey so far...








Reach and Presence - Hospitals



Network of Hospitals in India with bed capacity



Has a total bed capacity of 2,012 beds across 11 multi-specialty hospitals



Reach and Presence - OPD




Network of Outpatient Clinics in India



International Footprint





Has a network of 40 patient outreach centres in India

International footprint consists of 6 outpatient clinics in Africa



Expansion Plans in Progress



Investment Plans for Upcoming facilities

Nashik

- Bed Capacity 113
- •Capex Rs 25 Crore

Mumbai [Santa Cruz]


- Bed Capacity 175
- •Capex Rs 150 Crore

Mumbai [Ghatkopar]

- Current bed capacity 50.
- Addition 100 beds
- Capex Nil



Total capex planned - Rs. 175 Crore for addition of 388 beds



2 — Our Unique Business Model


is the key to our outperformance



Our Business Model - features Optimising Capex and Opex




- Lowest Capex and Opex per bed due to optimal use of real-estate
- Equipment planning and utilities planning
- In-house planning teams
- Focus on surgeries with higher ARPOB, better margins and return ratios
- Centralised procurement
- Gradual ramp-up of bed capacity
- Fully owned or O&M on revenue sharing (no fixed rentals, no security deposit or MG)





Typical concept of 200 (±20%) bed capacity set-up



Facilities 10-15 kms away


Local and Natural Footfalls from 4-5 kms radius helps to fill up ~50% beds

Balance ~50% - patients come in the name of doctors reducing thereby dependency on star doctors thus controlling doctor payout %



Our Business Models...-








Role of OPDs for expansion







Case for Expansion




The Opportunity Set




Population and Population Growth Rate of India (Historical and Expected)

CAGR (2014-2020)



Spilt of Indian Healthcare Industry by Segments

Total market size (2016): INR 9.2 trillion







The Opportunity Size

SHALBY MULTI-SPECIALTY HOSPITALS

Spilt of Public and Private Hospitals in India

Indian Healthcare Delivery Industry size (2015-2020) (INR in Trillion)







Recent transformation


SHALBY MULTI-SPECIALTY

- Private sector investment has been increasing due to change in mind-set and better returns on investment
- Healthcare businesses can also be profitable as long the costs are affordable
- The advent of information technology has given a fillip to the healthcare business making it both controllable and scalable
- Rising aspirational middle-class today is not averse to paying for quality healthcare services.
- Impact of health insurance, government schemes and emergence of medical tourism key drivers of positive change
- Healthcare today in India is evolving to be a larger consumer story than ever before










CAGR - 29% in 30 years. Currently growing @ 2-3%

Wide procedure penetration - to Tier 2 and 3 cities



Knee Replacement - the big opportunity






Surgery Count CAGR @32% in 23 years



Growth Drivers for Shalby







Conducive Government Policies Despite Challenges



Swastha Bharat, Smriddha Bharat. Demographic dividend realization impossible without proper healthcare

Rashtriya Samaj Beema Yojana: 100 mln families will get Rs 500,000 per year for their families to cover secondary and tertiary hospital expenses





100% depreciation on capex incurred, MAT credit can be availed for 15 years, all healthcare education and training services exempted from GST

State Policies include capital subsidy on purchase of medical equipment, capital investment subsidy on construction of tertiary-care hospitals and interest subvention, along with several other benefit















Revenue CAGR growth 31% in last 12 years




EBITDA CAGR growth 36% in last 12 years











Performance Q4FY19



Key Achievements of the Quarter



Cancer Surgeon team at
Shalby successfully
performed Esophageal
Cancer (Cancer of the
Food Pipe) through
Keyhole Surgery
avoiding the need for
Open Chest Surgery


Gall Bladder Cancer in an 84 year old patient cured at Shalby through surgery and treatment


Blockage in
Vein supplying blood
to Liver, removed in
a rare surgery at
Shalby Hospitals



IP and OP Count (Quarterly Trend)










Surgeries Count (Quarterly Trend)



Surgeries - Arthroplasty vs Others






Surgeries Count (Quarterly Trend)



Arthroplasty Vs Others





Performance Synopsis Q4 FY19



Particulars	Quarter Ended 31-03-19	% of Revenue	Quarter Ended 31-03-18	% of Revenue	Growth
Total Revenue (INR in million)	1153.9		1110.4		4%
Total EBITDA (INR in million)	169.8	14.7%	172.1	15.5%	(1%)
Bed Capacity (Nos.)	2012		2012		N.A
Operational Beds (Nos.)	1102		1102		N.A
Average Length of Stay	2.45		3.6		N.A
Occupancy (Beds)	417		396		5%
In-Patient Count (Nos.)	15316*		9998		53%
Out patient Count (Nos.)	77140		64189		20%
Surgeries Count	4893		4802		2%
ARPOB (In Rs.)	30760		30625		0.4%

^{*} Increase in IP Count is witnessed due to drastic increase of day care procedures like Radiation therapy, Dialysis etc in Units having < 2 years of Maturity Profile



Financial Highlights Q4FY19 Standalone




(INR in million)

Particulars	Quarter Ended 31-03-19	% of Revenue	Quarter Ended 31-03-18	% of Revenue	Growth
Revenue from Operations	1126.8		1083.7		4.0%
Other Income	27.1		26.7		1.6%
Total Income	1153.9		1110.4		3.9%
Expenses					
Materials & Consumables	316.5	27.4%	264.4	23.8%	
Fees to Doctors and Consultants	328.7	28.5%	300.1	27.0%	
Other Operative Expenses	35.3	3.1%	78.3	7.1%	
Employee Costs	217.1	18.8%	139.1	12.5%	
Administrative Expenses	69.5	6.0%	122.8	11.1%	
Advt. & Promotion	16.9	1.5%	33.5	3.0%	
Total Operational Expenses	984.1	85.3%	938.3	84.5%	
EBITDA	169.8	14.7%	172.1	15.5%	(1.3%)
Finance Cost	22.1		(3.1)		
Depreciation & Amortization Expense	78.8		64.1		
Profit before tax (PBT)	68.9		111.1		(38.0%)
Tax Expense	35.0		(71.8)		
Profit after tax (PAT)	33.9	2.9%	182.9	16.5%	(81.5%)




Financial Parameters Q4 FY19





ARPOB and ALOS (Quarterly)







^{*} Decrease in ALOS is witnessed due to drastic increase of day care procedures like Radiation therapy, Dialysis etc in Units having < 2 years of Maturity Profile












- **Cardiac Science**
- Other Ortho
- Nephrology




Self Pay






Surgery Count and Cost Structure Q4FY19





Bed Count Split(Quarterly)









Maturity Profile	Avg. Occupied Beds	Census Beds	Non-Census Beds	Operational Beds	Non- Operational Beds	Total Bed Capacity
4 years + (SG; Vijay; Krishna; Vapi)	159	325	57	382	212	594
2-4 years (Jabalpur, Indore)	124	309	52	361	115	476
< 2 years (Jaipur; Naroda; Surat; Mohali)	134	253	56	309	583	892
Total	417	887	165	1,102*	910	2,012

Note: The operational bed count of 1,102 considers 50 operational beds at Zynova-Shalby Hospital, Mumbai, for which no other operational parameters are tracked







Q4 FY 19 Q4 FY 18

Maturity Profile	IP Count	OP Count	Surgery Count
4 years + (SG; Vijay; Krishna; Vapi)	4005	29507	2807
2-4 years (Jabalpur, Indore)	3085	22736	937
< 2 years (Jaipur; Naroda; Surat; Mohali)	8226	24897	1,149
Total	15316	77140	4,893

Maturity Profile	IP Count	OP Count	Surgery Count
4 years + (SG; Vijay; Krishna; Vapi)	4294	30140	2963
2-4 years (Jabalpur, Indore)	3303	20575	1039
< 2 years (Jaipur; Naroda; Surat; Mohali)	2401	13474	800
Total	9998	64189	4802



Maturity Profile - Q4FY19 - with Revenue mix

Maturity Profile	% of Total Revenue	Arthroplasty	Non Arthroplasty	ARPOB(Rs)	ALOS(Days)	EBITDA %
4 years + (SG; Vijay; Krishna; Vapi)	51%	30%	21%	40966	3.57	27%
2-4 years (Jabalpur, Indore)	20%	4%	16%	20460	3.63	3.8%
< 2 years (Jaipur; Naroda; Surat; Mohali)	29%	9%	20%	27171	1.46	1.3%
Total	100%	43%	57%	30760	2.45	14.7%









IP and OP Count (Yearly Trend)





OP Count






Surgeries Count (Yearly Trend)



Surgeries Count: Arthroplasty vs Others






Surgeries Count (Yearly Trend)



Arthroplasty Vs Others





Performance Synopsis FY19

Particulars	Year Ended 31-03-19	% of Revenue	Year Ended 31-03-18	% of Revenue	Growth	
Total Revenue (INR in million)	4708.5		3942.35		19.4%	
Total EBITDA (INR in million)	908.7	19.3%	930.67	23.6%	(2.4%)	
Bed Capacity (Nos.)	201	12	2012	2	N.A	
Operational Beds (Nos.)	110)2	1103	N.A		
Average Length of Stay	2.7	7	3.7	N.A		
Occupancy (Beds)	41	3	335	23.3%		
In-Patient Count (Nos.)	5598	55985 *		32967		
Out patient Count (Nos.)	296,	197	222,9	32.8%		
Surgeries Count	19908		17,554		13.4%	
ARPOB (In Rs.)	31235		31564		(1.0%)	

^{*} Increase in IP Count is witnessed due to drastic increase of day care procedures like Radiation therapy, Dialysis etc in Units having < 2 years of Maturity Profile



Financial Highlights FY19 Standalone




(INR in million)

Particulars	Year ended 31-03-19	% of Revenue	Year ended 31-03-18	% of Revenue	Growth
Revenue from Operations	4611.1		3855.2		19.6%
Other Income	97.5		87.1		11.9%
Total Income	4708.5		3942.4		19.4%
Expenses					
Materials & Consumables	1215.4	25.8%	947.7	24.0%	
Fees to Doctors and Consultants	1243.1	26.4%	898.1	22.8%	
Other Operative Expenses	155.6	3.3%	326.7	8.3%	
Employee Costs	851.4	18.1%	447.9	11.4%	
Administrative Expenses	265.6	5.6%	319.6	8.1%	
Advt. & Promotion	68.8	1.5%	71.7	1.8%	
Total Operational Expenses	3799.8	80.7%	3011.7	76.4%	
EBITDA	908.7	19.3%	930.7	23.6%	(2.4%)
Finance Cost	71.4		121.3		
Depreciation & Amortization Expense	330.0		224.3		
Profit before tax (PBT)	507.3		585.01		(13.3%)
Tax Expense	186.2		144.9		
Profit after tax (PAT)	321.0	6.8%	440.2	11.2%	(27.1%)




Financial Parameters FY19





ARPOB and ALOS (Yearly)






^{*} Decrease in ALOS is witnessed due to drastic increase of day care procedures like Radiation therapy, Dialysis etc in Units having < 2 years of Maturity Profile










- **Cardiac Science**
- Other Ortho
- Nephrology









SHALBY MULTI-SPECIALTY HOSPITALS
















Maturity Profile - FY19 - with Revenue mix

Maturity Profile	% of Total Revenue	Arthroplasty	Non Arthroplasty	ARPOB(Rs)	ALOS(Days)	EBITDA %
4 years + (SG; Vijay; Krishna; Vapi)	51%	31%	20%	42107	3.32	30%
2-4 years (Jabalpur, Indore)	22%	4%	18%	20735	3.64	9.0%
< 2 years (Jaipur; Naroda; Surat; Mohali)	28%	10%	18%	29127	1.76	7.3%
Total	100%	45%	55%	31235	2.69	19.3%



Maturity Profile - Operational Parameters



FY 19 FY 18

Maturity Profile	IP Count	OP Count	Surgery Count
4 years + (SG; Vijay; Krishna; Vapi)	17019	115093	10792
2-4 years (Jabalpur, Indore)	13640	91021	4193
< 2 years (Jaipur; Naroda; Surat; Mohali)	25326	90083	4923
Total	55985	296197	19908

Maturity Profile	IP Count	OP Count	Surgery Count
4 years + (SG; Vijay; Krishna; Vapi)	15,989	110710	12,026
2-4 years (Jabalpur, Indore)	11,725	74,357	3,317
< 2 years (Jaipur; Naroda; Surat; Mohali)	5,253	37,903	2,211
Total	32967	222970	17554




Maturity Profile - FY19 - with Revenue mix

Maturity Profile	% of Total Revenue	Arthroplasty	Non Arthroplasty	ARPOB(Rs)	ALOS(Days)	EBITDA %
4 years + (SG; Vijay; Krishna; Vapi)	51%	30%	21%	42107	3.32	30%
2-4 years (Jabalpur, Indore)	22%	4%	18%	20735	3.64	9.0%
< 2 years (Jaipur; Naroda; Surat; Mohali)	28%	10%	18%	29127	1.76	7.3%
Total	100%	44%	56%	31235	2.69	19.3%



Shareholding Pattern







Dividend for FY 2018-19

SHALBY MULTI-SPECIALTY HOSPITALS

We take pleasure to inform that Company has recommended dividend of 5%.





Our Strengths and Differentiators



Experienced promoters with hands-on involvement

Strong brand, global leadership in Joint Replacement

Optimized
Business Model
now being
replicated

Increasing focus on Quaternary treatments such as Oncology and Organ transplants

Even after the IPO promoter holding is ~80%

Unleveraged Balance Sheet

Strong emphasis on governance and compliance

Leadership and succession plan in place





For more detailed information please click on the link below:

- Q4FY19 result
- Q3FY19 result
- Q2FY19 result
- Q1FY19 result
- Monitoring Agency Report for IPO proceeds
- FY19 result

Thank you



SHALBY LIMITED

Regd Off: Opp. Karnavati Club, S.G. Road, Ahmedabad – 380015, Gujarat, India. Phone: 079 4020 3000

Fax: +91 79 4020 3120 | Website: www.shalby.org | CIN: L85110GJ2004PLC044667

Script code: BSE: 540797 | NSE: SHALBY